Suppr超能文献

经内镜逆行胰胆管造影术后临床显著出血的发生率、预测因素和结局:一项当代多中心研究。

Incidence, Predictors, and Outcomes of Clinically Significant Post-Endoscopic Retrograde Cholangiopancreatography Bleeding: A Contemporary Multicenter Study.

机构信息

Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.

Division of Gastroenterology and Hepatology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada.

出版信息

Am J Gastroenterol. 2024 Nov 1;119(11):2317-2325. doi: 10.14309/ajg.0000000000002946. Epub 2024 Jul 5.

Abstract

INTRODUCTION

Clinically significant post-endoscopic retrograde cholangiopancreatography (ERCP) bleeding (CSPEB) is common. Contemporary estimates of risk are lacking. We aimed to identify risk factors of and outcomes after CSPEB.

METHODS

We analyzed multicenter prospective ERCP data between 2018 and 2024 with 30-day follow-up. The primary outcome was CSPEB, defined as hematemesis, melena, or hematochezia resulting in (i) hemoglobin drop ≥ 20 g/L or transfusion and/or (ii) endoscopy to evaluate suspected bleeding and/or (iii) unplanned healthcare visitation and/or prolongation of existing admission. Firth logistic regression was used. P values <0.05 were significant, with odds ratios (ORs) and 95% confidence intervals reported.

RESULTS

CSPEB occurred after 129 (1.5%) of 8,517 ERCPs (mean onset 3.2 days), with 110 of 4,849 events (2.3%) occurring after higher risk interventions (sphincterotomy, sphincteroplasty, precut sphincterotomy, and/or needle-knife access). Patients with CSPEB required endoscopy and transfusion in 86.0% and 53.5% of cases, respectively, with 3 cases (2.3%) being fatal. P2Y 12 inhibitors were held for a median of 4 days (interquartile range 4) before higher risk ERCP. After higher risk interventions, P2Y 12 inhibitors (OR 3.33, 1.26-7.74), warfarin (OR 8.54, 3.32-19.81), dabigatran (OR 13.40, 2.06-59.96), rivaroxaban (OR 7.42, 3.43-15.24), and apixaban (OR 4.16, 1.99-8.20) were associated with CSPEB. Significant intraprocedural bleeding after sphincterotomy (OR 2.32, 1.06-4.60), but not after sphincteroplasty, was also associated. Concomitant cardiorespiratory events occurred more frequently within 30 days after CSPEB (OR 12.71, 4.75-32.54).

DISCUSSION

Risks of antiplatelet-related CSPEB may be underestimated by endoscopists based on observations of suboptimal holding before higher risk ERCP. Appropriate periprocedural antithrombotic management is essential and could represent novel quality initiative targets.

摘要

简介

经内镜逆行胰胆管造影术(ERCP)后临床显著出血(CSPEB)较为常见。目前尚缺乏对其风险的评估。本研究旨在确定 CSPEB 的风险因素和结局。

方法

我们分析了 2018 年至 2024 年间进行的多中心前瞻性 ERCP 数据,随访时间为 30 天。主要结局是 CSPEB,定义为呕血、黑便或血便导致(i)血红蛋白下降≥20g/L 或输血和/或(ii)内镜检查评估疑似出血和/或(iii)计划外医疗就诊和/或现有住院时间延长。采用 Firth 逻辑回归。P 值<0.05 为有统计学意义,报告比值比(OR)和 95%置信区间。

结果

8517 例 ERCP 中有 129 例(1.5%)发生 CSPEB(平均发病时间为 3.2 天),4849 例事件中有 110 例(2.3%)发生在高风险介入后(括约肌切开术、括约肌成形术、预切开括约肌切开术和/或针刀进入)。CSPEB 患者分别有 86.0%和 53.5%需要内镜检查和输血,3 例(2.3%)死亡。在进行高风险 ERCP 前,P2Y12 抑制剂中位停药时间为 4 天(四分位间距 4)。在高风险介入后,P2Y12 抑制剂(OR 3.33,1.26-7.74)、华法林(OR 8.54,3.32-19.81)、达比加群(OR 13.40,2.06-59.96)、利伐沙班(OR 7.42,3.43-15.24)和阿哌沙班(OR 4.16,1.99-8.20)与 CSPEB 相关。括约肌切开术后(OR 2.32,1.06-4.60)而非括约肌成形术后显著的术中出血也与 CSPEB 相关。CSPEB 后 30 天内更常发生伴发心肺事件(OR 12.71,4.75-32.54)。

讨论

基于高风险 ERCP 前观察到的抗血小板药物停药不充分,内镜医生可能低估了与抗血小板药物相关的 CSPEB 风险。围手术期适当的抗血栓治疗至关重要,可能成为新的质量改进目标。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验